Results 211 to 220 of about 179,181 (243)

The hidden side of PD-L1

Nature Cell Biology, 2020
PD-L1 has been extensively described as the membrane-bound ligand of PD-1. A recent study discovered a previously unknown role for PD-L1, which is able to bind DNA and thus govern different pathways linked to either evasion of immune surveillance or tumour microenvironment inflammation.
Alison Jaccard, Ping-Chih Ho
openaire   +3 more sources

PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay

Current Drug Targets, 2020
Background: Immune checkpoint inhibitors targeting the programmed death receptor ligand 1 (PD-L1)/programmed death receptor 1 (PD-1) pathway represent a drastic change in the treatment landscape of RCC resulting in a dynamic and evolving scenario.
Cimadamore A., Massari F., Santoni M., Lopez-Beltran A., Cheng L., Scarpelli M., Montironi R., Moch H.   +7 more
openaire   +4 more sources

PD-L1 expression in meningiomas

Journal of Clinical Neuroscience, 2018
The management of meningiomas, especially inoperable, previously irradiated recurrent and anaplastic meningiomas has been challenging due to the paucity of effective chemotherapy. Numerous studies suggest that tumor-mediated immunosuppression may facilitate progression of many malignancies.
openaire   +2 more sources

[PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer].

Bulletin du cancer, 2018
The development of immune checkpoints inhibitors represents one of the major recent advances in oncology. Monoclonal antibodies directed against the programmed cell death protein 1 (PD-1) or its ligand (PD-L1) provides durable disease control, particularly in melanoma, lung, kidney, bladder and head and neck cancers.
Monneur, Audrey, Goncalves, Anthony, Bertucci, Francois   +2 more
openaire   +2 more sources

Relevance of host and tumor PD-L1 in PD-L1 pathway blockade

The Journal of Immunology, 2018
Abstract PD-L1 and PD-1 pathway blockade is a promising therapy against cancer. However, the mechanistic contribution of host and tumor PD-L1 and PD-1 signaling to therapeutic efficacy of PD-L1 and PD-1 blockade remains elusive. Using three tumor bearing mouse models that differ in their sensitivity to PD-L1 blockade, MC38, ID8, and B16 ...
Ilona Kryczek, Heng Lin, Shuang Wei, Michael Green, Weiping Zou   +4 more
openaire   +1 more source

PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1

Journal of Cancer Research and Clinical Oncology, 2019
To investigate the associations between programmed cell death ligand-1 (PD-L1) on tumor cells (TCs) or PD-L1 on tumor-infiltrating immune cells (TIICs) and the microsatellite instability (MSI) status in colorectal cancer (CRC).In total, 238 CRC patients were enrolled.
Hsiang-Ling Ho, Teh-Ying Chou, Shung-Haur Yang, Jeng-Kai Jiang, Wei-Shone Chen, Yee Chao, Hao-Wei Teng   +6 more
openaire   +2 more sources

PD-L1 on pain

Science Signaling, 2017
As well as being an immunosuppressive checkpoint, the tumor-associated cell surface molecule PD-L1 suppresses pain signaling in sensory neurons.
openaire   +1 more source

Beyond inhibition against the PD-1/PD-L1 pathway: development of PD-L1 inhibitors targeting internalization and degradation of PD-L1

RSC Medicinal Chemistry
This review clarifies the evolution of PD-L1 inhibitors and provides insights into the current development of PD-L1 inhibitors, especially targeting internalization and degradation of PD-L1.
Jiazheng Guo, Fengyi Yu, Kuojun Zhang, Sheng Jiang, Xiangyu Zhang, Tianyu Wang   +5 more
openaire   +2 more sources

Human PD-L1-binding immunoglobulins

2019
The invention relates to polypeptides, in particular polypeptides comprising an immunoglobulin domain, binding to human Programmed Death Ligand-1 (huPDL1) and to applications of such polypeptides such as for use as a medicament or for use as diagnostic agent, for example as an immunotracer.
Van Ginderachter, Jo, Raes, Geert, Devoogdt, Nick, Keyaerts, Marleen, Lecocq, Quentin, Xavier, Catarina, Breckpot, Karine, Broos, Katrijn, Bridoux, Jessica   +8 more
openaire   +3 more sources

Expression of PD-L1 in mastocytosis

Journal of the American Academy of Dermatology, 2016
Lawrence F. Kuklinski, Jinah Kim
openaire   +2 more sources